Shihao Chen
Founder & CEO Qlsf Biotherapeutics Inc.
Seminars
Thursday 25th June 2026
Translating Preclinical Insights to Clinical Success for a First-in-Class T-Cell Engager
1:30 pm
- Prediction of efficacious concentrations using translational PK/PD modelling
- Optimizing clinical delivery and safety with the use of step-up dosing
- Utilize potential biomarkers
Thursday 25th June 2026
Roundtable Discussion: Standardizing Safety Benchmarks by Establishing Collaborative In Vitro Frameworks to De-Risk T-Cell Engager Translation
2:00 pm
- Addressing the lack of commercialized GLP-standardized assays for pHLA and human-specific targets, and the resulting necessity for companies to develop bespoke, creative in-house solutions
- Evaluating current industry best practices by analyzing the non-clinical pathways of pioneers to establish a common technical foundation for the field
- Proposing collaborative strategies to share methodologies and validation data for in vitro assays to help move the industry toward a unified standard that can be more effectively presented to regulatory bodies
Thursday 25th June 2026
A PSMA-Targeted, CD2-Costimulating T-Cell Engager with Strong Preclinical Efficacy & a Favorable GLP Toxicology Profile
12:00 pm
- PSMA is highly expressed in prostate cancer, and single‑cell RNA sequencing of metastatic tumor‑infiltrating lymphocytes identifies CD2 as a broadly expressed co‑stimulatory receptor, particularly on CD8⁺ T cells
- QL535, a trispecific PSMA × CD3 × CD2 molecule (2+1+1 TECOS format), delivers CD3 activation and CD2 co‑stimulation to enhance cytotoxicity while limiting cytokine release compared with benchmark T‑cell engagers
- QL535 demonstrates superior PSMA‑dependent killing in vitro, sustained activity under repeated stimulation, dose‑responsive tumor regression in PSMA⁺ PDX models, and a favorable GLP toxicology profile in non‑human primates, supporting its clinical development for PSMA‑positive prostate cancer
